Search - tctmd.com

Displaying 1 - 20 of 230

Sort: Relevancy | Date

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Daily News

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Michael O'Riordan

March 03, 2026

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: Essence-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

Advertisement

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

What’s Going to Be Hot at ACC 2026

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Side Effects of Statins Might Be Overstated: CTT Collaboration

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Top Prevention Stories of 2025

TCTMD’s Top 10 Most Popular Stories for November 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Olezarsen Brings Moderately High Triglycerides Under Control: Essence-TIMI 73b

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content